您当前的位置: 首页 > 综合资讯

综合资讯共计 6,228 条信息

      全选  导出

1 Medicalxpress,1月17日,Additional antibodies may protect against COVID 2022-01-26

When we talk about antibodies against COVID-19,we tend to mean the so-called neutralizing antibodies,that offer protection by blocking the virus from invading our cells.Now,a new study from Lund University in Sweden has revealed that non-neutralizing antibodies may also be important in providing protection against COVID. "Our results indicate that non-neutralizing antibodies could also provide protection.This would mean that we have broader protection from antibodies than previously thought,making us less vulnerable to mutations of the virus.It warrants further investigation,"says Pontus Nordenfelt who led the study and is aresearcher at Lund University. In its efforts to produce vaccines and treatments,the research community has focused on neutralisingantibodies,which prevent the spike protein of the virus from binding to the surface protein on our cells. In alarge project led by researchers at Lund University,a more detailed study has been carried out on how the immune system also fights off the virus by means of phagocytosis,the ability to ingest foreign particles,in COVID-19 patients. Phagocytosis is atype of cleansing mechanism during which the immune system's players target potential threats,such as bacteria or viruses,and ingests them,and this mechanism is facilitated if the harmful substance is marked by an antibody.The results,published in athemed issue of Frontiers in Immunology,indicate that non-neutralizing antibodies are also important in the fight against COVID—through this mechanism. "We observed that many of the antibodies that develop in response to COVID-19 are opsonising,i.e.they signal to the immune system's phagocytes to ingest the virus.Our results indicate that non-neutralizing antibodies,so long as they are able to opsonise,are also able to provide an effective response to the virus,"says Pontus Nordenfelt. The findings are supported by experiments on mice,in which the non-neutralizing antibodies protected the animals from COVID-19 infection. The research team also discovered that the amount of neutralizing antibodies affects the process of phagocytosis. The team identified and isolated immune system cells from the blood of recovered COVID-19 patients.Using several techniques,they mapped which immune cells interact with the virus's spike protein and identified the antibody binding sites.Then,using flow cytometry,they studied how these antibodies affect phagocytosis. 查看详细>>

来源: 点击量:3

2 Medicalxpress,1月14日,Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19 2022-01-26

A research team led by Prof.Stephan Ludwig,a virologist at the Institute of Virology at the University of Münster,has found anew dual attack mode of action while working on the development of adrug candidate against SARS-CoV-2 infections.This could constitute the basis for abroadly effective drug to fight COVID-19.The data,which have now been published in the journal Cellular and Molecular Life Sciences,provided the basis for the approval issued by the German Institute of Drugs and Medicinal Products for aclinical study currently being worked on. The drug can not only inhibit the proliferation of SARS-CoV-2 viruses in cells,but also reduce the exaggerated immune response which represents aserious problem in severe cases of COVID."In the results we have published,we have been able for the first time to show such adual action for an anti-COVID-19 agent,"explains Stephan Ludwig,who has overall responsibility for the research work.The team is collaborating with researchers at the Universities of Würzburg and Tübingen,the German Primate Centre in Göttingen,and the'Atriva Therapeutics'start-up established by scientists of the Universities of Münster,Tübingen and Gießen. The active agent in question,called Zapnometinib or ATR-002,which was originally under development as anti-flu medication,was effective in avariety of cell culture models—including activity against all tested variants of SARS-CoV-2,which also implies abroad applicability in facing up to any coming variants in the future.Animal testing to confirm these findings are currently under-way."Positive results from the still ongoing clinical study in humans might already lead to an emergency approval this year for anew,broadly effective COVID-19 medication.The benefit is clear,"says Stephan Ludwig. 查看详细>>

来源: 点击量:0

3 Medicalxpress,1月13日,WHO recommends two new drugs to treat patients with COVID-19 2022-01-26

The drug baricitinib(a type of drug known as aJanus kinase(JAK)inhibitor,also used to treat rheumatoid arthritis)is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids,says aWHO Guideline Development Group of international experts in The BMJ today. Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation,with no observed increase in adverse effects. The WHO experts note that baricitinib has similar effects to other arthritis drugs called interleukin-6(IL-6)inhibitors so,when both are available,they suggest choosing one based on cost,availability,and clinician experience.It is not recommended to use both drugs at the same time. However,the experts advise against the use of two other JAK inhibitors(ruxolitinib and tofacitinib)for patients with severe or critical COVID-19 because low certainty evidence from small trials failed to show benefit and suggests apossible increase in serious side effects with tofacitinib. In the same guideline update,WHO also makes aconditional recommendation for the use of the monoclonal antibody sotrovimab in patients with non-severe COVID-19,but only in those at highest risk of hospitalization,reflecting trivial benefits in those at lower risk. A similar recommendation has been made by WHO for another monoclonal antibody drug(casirivimab-imdevimab).The experts also note that there were insufficient data to recommend one monoclonal antibody treatment over another—and they acknowledge that their effectiveness against new variants like omicron is still uncertain. As such,they say guidelines for monoclonal antibodies will be updated when additional data become available. 查看详细>>

来源: 点击量:1

4 1月13日_研究发现阻断人类细胞BRD2的产生可防止SARS-CoV-2感染 2022-01-26

Phys.org网站1月13日消息,加州大学旧金山分校的研究人员发现,阻断BRD2的产生可以防止SARS-CoV-2感染多种人类细胞类型,这种被称为BRD2的蛋白质可调节ACE2受体。相关研究发表在期刊《自然·细胞生物学》上。 BRD2是由人类细胞产生的蛋白质,可以调节其他基因的表达,包括那些在某些癌症中有助于促进肿瘤生长的基因。该蛋白质和其他与之相关的蛋白质目前正在临床试验中作为抗癌药物的靶标进行研究。研究人员在寻找影响SARS-CoV-2附着在各种细胞类型能力的人类宿主蛋白时发现,BRD2可调节ACE2。这些细胞包括来自肺、心脏和鼻腔等组织的细胞,这些组织特别容易感染SARS-CoV-2和因COVID-19疾病而被长期损害。研究人员筛选了可影响SARS-CoV-2与人类细胞相互作用的2325种细胞蛋白。研究发现,针对BRD2的现有药物可以阻止人类易感细胞以及仓鼠感染SARS-CoV-2。研究人员发现,抑制BRD2在抑制ACE2产生和COVID-19传染性方面的效果几乎与直接抑制ACE2基因本身相同。 研究人员表示,需要进行更多的研究来验证可调节BRD2的新药的安全性和有效性。例如,研究人员发现,抑制BRD2会抑制干扰素的产生,干扰素是人体炎症反应中的关键蛋白质。另外,研究人员认为,可以用CRISPR基因编辑技术寻找药物靶点。 查看详细>>

来源: 点击量:0

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190